Efficacy of Human Monoclonal Antibodies against H5N1 Influenza
Author Information
Author(s): Cameron P. Simmons, Nadia L. Bernasconi, Amorsolo L. Suguitan Jr., Kimberly Mills, Jerrold M. Ward, Nguyen Van Vinh Chau, Tinh Tran Hien, Federica Sallusto, Quang Ha Do, Jeremy Farrar, Menno D. de Jong, Antonio Lanzavecchia, Kanta Subbarao
Primary Institution: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
Hypothesis
Can human monoclonal antibodies (mAbs) be generated to effectively prevent and treat H5N1 influenza?
Conclusion
The study demonstrates that human monoclonal antibodies can be rapidly generated and are effective for the prevention and treatment of H5N1 infection in a mouse model.
Supporting Evidence
- Monoclonal antibodies FLA3.14 and FLA5.10 provided protection from lethality in mice.
- Therapeutic doses of mAbs conferred robust protection from lethality up to 72 hours post-infection.
- mAbs demonstrated cross-reactivity against different strains of H5N1.
Takeaway
Scientists created special antibodies from people who got better from bird flu, and these antibodies helped protect mice from getting sick.
Methodology
The study involved generating neutralizing human monoclonal antibodies from memory B cells of convalescent patients and testing their efficacy in vitro and in vivo using a murine model.
Potential Biases
Potential bias in the selection of antibody clones and the small sample size of donors.
Limitations
The study was conducted in mice, and the efficacy in humans remains to be established.
Participant Demographics
Four adult blood donors from Vietnam who had recovered from H5N1 infection.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website